Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of HRS-1893 in obstructive hypertrophic cardiomyopathy
CTR20252246Phase 3Active
- Sponsor
- Shandong Sende
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-1893 in hypertrophic cardiomyopathy (HCM), sponsored by Shandong Sende. Started Aug 2025; status: active.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on CTR20252246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252246.